scholarly journals Cystic Fibrosis Transmembrane Conductance Regulator Regulates Epithelial Cell Response toAspergillusand Resultant Pulmonary Inflammation

2012 ◽  
Vol 185 (3) ◽  
pp. 301-310 ◽  
Author(s):  
Neelkamal Chaudhary ◽  
Kausik Datta ◽  
Frederic B. Askin ◽  
Janet F. Staab ◽  
Kieren A. Marr
Keyword(s):  
Cystic Fibrosis ◽  
Epithelial Cell ◽  
Cell Response ◽  
Pulmonary Inflammation ◽  
Transmembrane Conductance Regulator ◽  
Transmembrane Conductance ◽  
Cystic Fibrosis Transmembrane

scholarly journals “Pathogen Eradication” and “Emerging Pathogens”: Difficult Definitions in Cystic Fibrosis

2018 ◽  
Vol 56 (9) ◽  
Author(s):  
Peter H. Gilligan ◽  
Damian G. Downey ◽  
J. Stuart Elborn ◽  
Patrick A. Flume ◽  
Sebastian Funk ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pulmonary Inflammation ◽  
Airway Disease ◽  
Current Treatment ◽  
Transmembrane Conductance Regulator ◽  
Common Complication ◽  
Emerging Pathogens ◽  
Transmembrane Conductance ◽  
Cystic Fibrosis Transmembrane ◽  
Chronic Use

ABSTRACTInfection is a common complication of cystic fibrosis (CF) airway disease. Current treatment approaches include early intervention with the intent to eradicate pathogens in the hope of delaying the development of chronic infection and the chronic use of aerosolized antibiotics to suppress infection. The use of molecules that help restore CFTR (cystic fibrosis transmembrane conductance regulator) function, modulate pulmonary inflammation, or improve pulmonary clearance may also influence the microbial communities in the airways. As the pipeline of these new entities continues to expand, it is important to define when key pathogens are eradicated from the lungs of CF patients and, equally important, when new pathogens might emerge as a result of these novel therapies.

Sign in / Sign up

Export Citation Format

Share Document